APO-SITAGLIPTIN sitagliptin100 mg (as phosphate monohydrate) tablet blister pack

Nchi: Australia

Lugha: Kiingereza

Chanzo: Department of Health (Therapeutic Goods Administration)

Viambatanisho vya kazi:

sitagliptin phosphate monohydrate, Quantity: 128.5 mg (Equivalent: sitagliptin, Qty 100 mg)

Inapatikana kutoka:

Arrotex Pharmaceuticals Pty Ltd

INN (Jina la Kimataifa):

sitagliptin phosphate monohydrate

Dawa fomu:

Tablet

Tungo:

Excipient Ingredients: iron oxide yellow; macrogol 8000; microcrystalline cellulose; iron oxide red; titanium dioxide; calcium hydrogen phosphate; magnesium stearate; hyprolose; hypromellose; croscarmellose sodium; purified talc

Njia ya uendeshaji:

Oral

Vitengo katika mfuko:

28

Dawa ya aina:

(S4) Prescription Only Medicine

Matibabu dalili:

Sitagliptin is indicated for the treatment of diabetes mellitus type 2 in persons 18 years of age and older who have failed dietary measures and exercise:,- as monotherapy, as an adjunct to diet and exercise to improve glycaemic control in patients with type 2 diabetes mellitus, when metformin cannot be used.,- as dual combination therapy, with metformin, or with a sulfonylurea, or with a thiazolidinedione where the use of a thiazolidinedione is considered appropriate.,- as triple combination therapy with metformin and a sulfonylurea when combination therapy with both agents does not provide adequate glycaemic control.,- as add-on combination therapy with insulin (with or without metformin).

Bidhaa muhtasari:

Visual Identification: Beige, round biconvex coated tablet. Engraved "SIT" over "100" on one side and "APO" on the other side.; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 18 Months; Container Temperature: Store below 25 degrees Celsius

Idhini hali ya:

Licence status A

Idhini ya tarehe:

2015-04-15